References:
  1. F. Bray, J. Ferlay, I. Soerjomataram, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin., 68 (6) (2018), pp. 394-424.
  2. Osses DF, Roobol MJ, Schoots IG. Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. Int J Mol Sci . 2019;20(7):1637.
  3. Mottet, N.; Bellmunt, J.; Bolla, M.; Briers, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.; Henry, A.M.; Joniau, S.; et al. Eau-estro-siog guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 2017, 71, 618–629.
  4. Jiang H, Li H, Li A, et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget . 2016;7(44):72076-72083.
  5. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223–226.
  6. Read JA, Choy ST, Beale PJ, Clarke SJ. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer. 2006;55:78–85.
  7. Guo Y, Shi D, Zhang J, et al. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy. J Cancer . 2019;10(1):81-91.
  8. Peng D, Zhang C, Tang Q, Zhang L, Yang K, Yu X. et al. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy. BMC Urol. 2018;18:20.
  9. Peng D, Zhang C, Gong Y, Hao H, Guan B, Li X. et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 2018;8:794.
  10. Chen X, Xue L, Wang W, Chen H, Zhang W, Liu K. et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6:41370–82.
  11. Jiang H, Li H, Li A, Tang E, Xu D, Chen Y. et al. Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 2016;7:72076–83.
  12. Lukes M, Urban M, Záleský M, Zachoval R, Herácek J, Zdárský E. Prostate-specific antigen: current status. Folia Biol (Praha) . 2001;47(2):41-49.
  13. Nassir AM. A piece in prostate cancer puzzle: Future perspective of novel molecular signatures. Saudi J Biol Sci . 2020;27(4):1148-1154.
  14. Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol . 2013;31(5):566-571.
  15. Milanese G, Dellabella M, Fazioli F, et al. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer. J Urol . 2009;181(3):1393-1400.
  16. Yuksel OH, Urkmez A, Akan S, Yldirim C, Verit A. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer. Asian Pac J Cancer Prev . 2015;16(15):6407-6412.
  17. Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. Cancer Biomark . 2015;15(3):317-323.
  18. Adhyatma KP, Warli SM. Diagnostic Value of Platelet-To-Lymphocyte Ratio in Prostate Cancer. Open Access Maced J Med Sci . 2019;7(7):1093-1096.
  19. Wang J, Zhou X, He Y, et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Medicine (Baltimore) . 2018;97(40):e12504.
  20. Adhyatma KP, Prapiska FF, Siregar GP, Warli SM. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio. Open Access Maced J Med Sci . 2019;7(10):1628-1630.
  21. Fu S, Zhang X, Niu Y, Wang RT. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia. Asian Pac J Cancer Prev . 2018;19(3):699-702.
  22. Cong L, Hu L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. Int Immunopharmacol . 2017;46:75-79.
  23. Shen XB, Zhang YX, Wang W, Pan YY. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival. Med Sci Monit . 2019;25:5630-5639.
  24. Xu SS, Li S, Xu HX, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroenterol . 2020;26(8):828-838.
  25. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer . 2004;40(15):2293-2306.
  26. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol . 2010;30(12):2362-2367.
  27. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature . 2008;454(7203):436-444.
  28. Wang C, Guo M, Zhang N, Wang G. Association of body mass index and outcomes following lobectomy for non-small-cell lung cancer. World J Surg Oncol . 2018;16(1):90.
  29. Sejima T, Iwamoto H, Masago T, et al. Low pre-operative levels of serum albumin predict lymph node metastases and ultimately correlate with a biochemical recurrence of prostate cancer in radical prostatectomy patients. Cent European J Urol . 2013;66(2):126-132.
  30. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol . 2015;7(6):378-387.
Legends:
Table-1: The patient characteristics and laboratory results
Table-2: Comparision of the parameters for ROC analysis
Figure-1: The ROC analysis of the parameters